Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis

Next Previous
Trial Profile

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUR 101 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms INDUS-2
  • Sponsors Aurigene Discovery Technologies; Aurigene Oncology

Most Recent Events

  • 15 Apr 2021 Status changed from active, no longer recruiting to completed.
  • 28 Dec 2020 Planned End Date changed from 15 Mar 2021 to 30 Apr 2021.
  • 28 Dec 2020 Planned primary completion date changed from 15 Nov 2020 to 20 Mar 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top